ArticleClinical kidney journal2026
AI and speech-based identification of cognitive impairment in maintenance haemodialysis-the ASPIRE study.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment (CI) is common among individuals receiving maintenance haemodialysis and is associated with impaired treatment adherence, reduced quality of life, and mortality. However, CI often remains under-recognized in nephrology care because existing diagnostic approaches are resource-intensive. Speech-based artificial intelligence (AI) is a promising approach for identifying CI through analysis of speech characteristics. This proof-of-concept study investigated whether a speech-based AI model could identify Montreal Cognitive Assessment (MoCA)-based CI and distinguish individuals receiving haemodialysis from clinically relevant controls. Methods: Adults receiving maintenance haemodialysis and controls completed the MoCA and speech tasks. Participants were categorized into low-, moderate-, and high-risk CI groups according to MoCA scores. Acoustic, linguistic, and multimodal speech features were extracted using machine-learning models. Model performance was evaluated. Results: Speech-based AI differentiated individuals receiving haemodialysis from controls ( Conclusion: Speech-based AI suggested potential as a scalable, non-invasive, and low-burden approach for identifying CI. Verbal fluency tasks and multimodal speech analysis showed the strongest classification performance. Although larger multicentre studies are needed, these findings provide proof of concept that speech may serve as a clinically relevant biomarker of CI in nephrology and support further validation using comprehensive neuropsychological assessment as a reference standard.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.